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Abstract
Background: Skeletal muscle undergoes rapid atrophy upon denervation and the underlying mechanisms are
complicated. FOXO3a has been implicated as a major mediator of muscle atrophy, but how its subcellular location
and activity is controlled during the pathogenesis of muscle atrophy remains largely unknown. MST1 (Mammalian
Sterile 20-like kinase 1) is identified as a central component of the Hippo signaling pathway. MST1 has been shown
to mediate phosphorylation of FOXO3a at Ser207. Whether this MST1-FOXO signaling cascade exerts any functional
consequence on cellular homeostasis remains to be investigated.
Result: We identified that MST1 kinase was expressed widely in skeletal muscles and was dramatically up-regulated
in fast- but not slow-dominant skeletal muscles immediately following denervation. The results of our histological
and biochemical studies demonstrated that deletion of MST1 significantly attenuated denervation-induced skeletal
muscle wasting and decreased expression of Atrogin-1 and LC3 genes in fast-dominant skeletal muscles from three-
to five-month-old adult mice. Further studies indicated that MST1, but not MST2, remarkably increased FOXO3a
phosphorylation level at Ser207 and promoted its nuclear translocation in atrophic fast-dominant muscles.
Conclusions: We have established that MST1 kinase plays an important role in regulating denervation-induced
skeletal muscle atrophy. During the early stage of muscle atrophy, the up-regulated MST1 kinase promoted
progression of neurogenic atrophy in fast-dominant skeletal muscles through activation of FOXO3a transcription
factors.
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Background
Skeletal muscle atrophy occurs upon denervation and dis-
use [1], as well as during aging and [2] under many cata-
bolic disease states, including cardiac and renal failure,
sepsis, cancer cachexia and diabetes [3-7]. During the
pathogenesis of muscle atrophy, protein synthesis is signif-
icantly suppressed largely due to the inhibition of the IGF-
1/PI3K/Akt pathway [8]. Protein degradation is accelerated
due to activation of both the ubiquitin-proteasome system
and autophagy, which work coordinately to remove the
myofibrillar proteins and myocyte organelles and thus
results in rapid loss of muscle mass and contractile func-
tion [9,10]. Expression of two E3 ligase genes, Atrogin-1
(MAFbx) and MuRF-1, as well as several autophagy genes,
including LC3, Bnip-3 and Gabarapl1, are shown to be
rapidly up-regulated at an early stage of multiple types of
muscle atrophy [9,11,12]. FOXO3a transcription factor is
able to bind to its consensus DNA-binding motif -
TTGTTTAC - in the promoter regions of several of these
atrogenes, including Atrogin-1, LC3, Bnip3 and Gabarapl1
[13-15]. Transactivation of these atrogenes by FOXO3a
together with other transcription regulatory mechanisms,
including NFB and myogenic factors, results in the initia-
tion of muscle atrophy [13,16-18].
The subcellular localization and activity of FOXO
transcription factors are regulated by multiple post-
translational modifications (PTM), including phosphory-
lation, ubiquitination and acetylation [19,20]. Some of
these modifications of FOXO factors have been reported
to regulate its activity and subcellular location in skeletal
muscle [21-25]. Under physiological conditions, in
response to insulin and/or IGF-1 signaling, FOXO
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transcription factors are phosphorylated and thus inhib-
ited by the IGF-1/PI3K/Akt pathway. Akt kinases phos-
phorylate FOXO at multiple sites and create binding
sites for 14-3-3 proteins, causing sequestration of FOXO
factors in the cytosol [26]. In response to atrophy sti-
muli, activity of IGF-1/PI3K/Akt pathway is largely
decreased [27], which results in the dephosphorylation
of FOXO transcription factors, allowing its dissociation
with 14-3-3 proteins and thus nuclear translocation
[20,28]. Beyond phosphorylation and inhibition of
FOXO by Akt kinases, whether there is any other regu-
latory mechanisms functioning upstream of FOXO fac-
tors during the pathogenic process of skeletal muscle
atrophy remains to be investigated.
The mammalian Ste20-like kinase (MST) family is
widely expressed in multiple tissues and consists of four
members: MST1, MST2, MST3 and MST4 [29-34]. MST1
kinase was shown to be activated under multiple stress
conditions, including oxidative stress [29] and activation
of caspases [35,36]. As a central component of the mam-
malian Hippo signaling cascade [37], MST1 transcript was
found in multiple skeletal muscles and in cardiac muscle
[38]. In cardiac muscle, MST1 kinase has been shown to
co-localize with and be capable of phosphorylating cardiac
troponin I in vivo [39]. During the pathological process of
myocardial infarction and hypertension-induced cardiac
hypertrophy, MST1 kinase is activated and results in apop-
tosis of cardiomyocytes [40].
It has been identified that MST1 was activated through
cleavage by caspase-3 during in vitro differentiation of the
myoblast [41]. Cleaved MST1 translocates into the nucleus
and promotes chromatin condensation and myotube dif-
ferentiation. Whether MST1 plays any role during in vivo
differentiation of skeletal muscle is unknown. Under
in vivo conditions, fiber type composition of mammalian
skeletal muscles is well determined during postnatal devel-
opment [42,43]. Immediately after birth, multiple mouse
skeletal muscles contain both slow- and fast-twitch fibers;
following postnatal development and growth, fiber type
composition of skeletal muscles is fully differentiated and
maintained throughout adulthood before aging. However,
the underlying molecular mechanisms are still largely
elusive.
It has been identified that a conserved MST-FOXO sig-
naling pathway regulates subcellular localization and
transactivation function of FOXO transcription factors in
neurons [30]. Upon oxidative stress, neuronal MST1
kinase is activated and phosphorylates FOXO proteins at a
conserved serine site. The phosphorylated FOXO factors
dissociate with 14-3-3 proteins and translocate into neuro-
nal nucleus to activate its downstream pro-apoptotic
genes, thus resulting in apoptosis of the neuron [30]. How-
ever, whether the function of this conserved MST-FOXO
signaling pathway is fundamental in regulating any patho-
physiological process in vivo is still not well understood.
In the present study, we examined expression of MST1
in multiple striated muscles during postnatal development.
We observed that the protein level of MST1 was enriched
at early postnatal stages and dramatically declined in
adulthood. In order to elucidate whether MST1 plays any
role during the pathological remodeling process of adult
skeletal muscles, we performed sciatic denervation on hin-
dlimb muscles from three- to five-month-old adult wild
type (WT) and MST1 knockout (KO) mice. Through bio-
chemical and histological studies, we identified that MST1
kinase was a key regulator of denervation-induced atrophy
in fast- but not in slow-dominant skeletal muscles. Imme-
diately following denervation, MST1 promoted increases
in gene expression of LC3 and Atrogin-1 through activa-
tion of FOXO3a. MST1 deficient fast-dominant muscles
in three- to five-month-old adult mice showed signifi-
cantly attenuated progression of denervation-induced
atrophy. Thus functioning upstream of FOXO3a transcrip-
tion factor, MST1 kinase provides a potential therapeutic
target for the clinical treatment of skeletal muscle atrophy.
Results
MST1/2 kinases are widely expressed in multiple skeletal
muscles and enriched at the neonatal stage
In order to investigate the function of MST1 under patho-
physiological conditions, we initially examined protein
expression of MST1/2 kinases and their downstream tran-
scriptional factor, FOXO3a, in multiple striated muscles,
including cardiac muscle, diaphragm muscle, soleus (Sol),
tibial anterior (TA), gastrocnemius (Gas) and extensor
digitorum longus (EDL) muscles (Figure 1A). Densitome-
try analysis revealed that expression of MST1/2 kinases
and FOXO3a was more predominant in cardiac muscle
and slow fiber-dominant soleus muscles, compared with
fast-dominant TA, gastrocnemius and EDL muscles
(Figure 1B-D). Although it has been shown that transcripts
of mammalian Hippo signaling components are found in
multiple skeletal muscles and cardiac muscle [38], our
data identified that the amount of protein of MST1/2
kinases was enriched in slow-dominant muscles and car-
diac muscle. This suggests differential roles played by
MST1/2 kinases in maintaining physiological homeostasis
of different striated muscles.
To investigate whether the differential expression of
MST1 kinase in fast- and slow-dominant muscles is
established during postnatal development, we examined
expression of MST1 kinase in fast- and slow-dominant
muscles at different postnatal stages (Figure 1E, F). The
results of Western blotting and densitometry revealed
that the amount of MST1 kinase protein was at its high-
est level on postnatal Day 1 in cardiac muscle and
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multiple skeletal muscles, including the diaphragm,
soleus and tibial anterior muscles (Figure 1E, F). From
postnatal Day 1 to Day 21, protein levels of MST1 were
continuously down-regulated in both slow-dominant
soleus and fast-dominant TA muscles. At postnatal Day
21 (wean age), MST1 kinase protein level in soleus mus-
cle remained 30.2 ± 0.01% of that at postnatal Day 1. In
fast-dominant TA muscle at postnatal Day 21, MST1
protein level remained barely detectable. Thus, MST1
kinase decreased in soleus muscle at a slower rate com-
pared with that in fast-dominant TA muscle, suggesting
that differential expression of MST1 kinase in slow- ver-
sus fast-muscle is determined during postnatal develop-
ment of skeletal muscles. Our data identified the
differential expression pattern of MST1 kinase in slow-
versus fast-dominant muscles and implicated the MST1
gene as potentially regulated by the postnatal myogenic
regulatory program.
MST1 kinase is up-regulated during muscle atrophy
In order to elucidate the function of MST1 during the
pathological remodeling process of adult skeletal mus-
cles, we performed sciatic denervation on hindlimb mus-
cles from three- to five-month-old adult WT and MST1
KO mice. It has been shown in the literature that seven
days after denervation, protein degradation mechanisms
were fully activated within myofibers [9,11]; and fourteen
days after denervation, muscle mass and myofiber size
were both dramatically decreased compared with contral-
ateral level [16]. We, therefore, collected contralateral
and denervated muscle samples at denervation Days 3, 7
and 14, and examined transcription of muscle atrophy
genes, and compared muscle mass and myofiber size.
Quantitative PCR revealed that MST1 gene transcrip-
tion was up-regulated at three and seven days after
denervation (Figure 2A). Western blotting also revealed
that protein levels of MST1 and MST2 kinases were
Figure 1 MST1 is expressed in striated muscles and enriched at early stage of postnatal muscle development. A. Expressions of MST1/2
and FOXO3a in striated muscles from three-month-old adult wild type mice were identified by Western blotting. B-D. Densitometry analysis
showed the expressions of MST1/2 kinases were enriched in cardiac muscle, diaphragm as well as soleus muscles, which contain significant
amount of type I fibers. E. Representative blotting shows protein level of MST1 was decreased during postnatal development in diaphragm,
cardiac, TA and soleus muscles. F. Quantification of muscular MST1 expression during postnatal development.
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immediately up-regulated in TA muscle following dener-
vation (Figure 2B, C). One week after denervation, the
increase in MST1 kinase occurred in fast-dominant TA,
Gas and EDL muscles, but much less dramatic in slow-
dominant soleus and flexor digitorum brevis (FDB) mus-
cles (Figure 2D, E), indicating MST1 kinase function
regulates neurogenic muscle atrophy in a myofiber type-
dependent manner. Thus, MST1 kinase function pro-
vides a potential mechanism mediating fast- but not
slow-dominant muscle atrophy.
We also observed increased MST1 kinase protein level
in gastrocnemius muscle following two weeks of hindlimb
unloading (Additional file 1). Interestingly, MST2 protein
level was not altered in this model of muscle atrophy, indi-
cating MST1 and MST2 kinases play differential roles in
mediating the occurrence of muscle atrophy. In a 48-hour
starvation-induced muscle atrophy model, neither MST1
nor MST2 kinase protein level was altered in the gastro-
cnemius muscle examined (Additional file 1).
MST1 deficient fast-dominant skeletal muscles are
resistant to denervation-induced atrophy
The rapid increase in MST1 protein levels in fast-dominant
muscles during denervation-induced atrophy suggests that
MST1 kinase may functionally contribute to the muscle
wasting process. However, it might also reflect an accumu-
lation of undegraded protein in atrophying myofibers. In
order to elucidate whether the up-regulated MST1 kinase
exerts any functional influence on neurogenic muscle atro-
phy, we examined atrophy process in muscles from three-
to five-month-old adult WT and MST1 KO littermate
mice. MST1 KO mice were generated as previously
described and was a kind gift from Dr. Wufan Tao [44].
Genomic deletion of exon 4 resulted in a reading frame
shift and a premature stop codon in exon 5 [44]. We initi-
ally observed the normalized muscle mass of fast-dominant
TA and gastrocnemius muscles were decreased in adult
MST1 KO mice (Additional file 2). It has been demon-
strated that MST1 was activated during myoblast differen-
tiation [41]. However, whether MST1 is necessary for
myogenic differentiation of myoblast in vivo is unknown.
Our data suggest that MST1 expression was predominant
in neonatal mouse skeletal muscles; MST1 was potentially
involved in regulating postnatal development of fast-domi-
nant muscles, and represents a neonatal gene program in
skeletal myofiber.
We examined the pathological process of denervation-
induced atrophy in adult WT and MST1 KO mice, by
measuring muscle mass and myofiber size. Muscle mass
data revealed that MST1 deficient gastrocnemius (Gas)
Figure 2 MST1 kinase is dramatically increased during denervation-induced atrophy in fast-dominant muscles from adult mice.
A. Quantitative PCR showed mRNA of MST1 was continuously increased three and seven days after denervation. B and C. Western blotting and
densitometry showed MST1 and MST2 protein levels were both increased during the process of denervation-induced atrophy in TA muscle.
D and E. Seven days after denervation, MST1 protein levels were dramatically increased in multiple fast-dominant muscles (TA, Gas and EDL),
but not in slow-dominant soleus and FDB muscles. *P < 0.05 by two-tailed Student’s test.
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and TA muscles were significantly resistant to denerva-
tion-induced muscle wasting (Figure 3A, B). Seven and
fourteen days after denervation, wild type TA muscle
mass decreased to 64.47% ± 2.4% and 50.81% ± 2.5% of
contralateral level, respectively; while MST1 deficient
TA muscle mass remained at 74.43% ± 1.36% and
66.35% ± 2.56% of its contralateral level (Figure 3B).
Gastrocnemius muscle mass data measured seven and
fourteen days after denervation also indicated that
MST1 deficiency protected the muscle against denerva-
tion-induced atrophy (Figure 3A). Myofiber area quanti-
fication using alpha-laminin staining on TA muscle
cryosections also revealed better preservation of myofi-
ber size in MST1 deficient TA muscles fourteen days
after denervation (Figure 3C). Although the myofiber
size of MST1 deficient TA muscles was generally smal-
ler than that in WT muscles under innervated condi-
tions, normalized myofiber area in denervated MST1
deficient TA muscle was better preserved by more than
15% than that of WT myofibers on average (Figure 3D).
Fourteen days after denervation, myofiber size distribu-
tion calculated from MST1 deficient TA muscles
showed a delayed leftward shift from its contralateral
conditions (Figure 3E, F). Thus, we identified that defi-
ciency in MST1 kinase protected fast-dominant skeletal
muscles against denervation-induced atrophy. The rapid
increase in MST1 immediately following denervation
potentially represents a pro-atrophy mechanism.
MST1 deficiency does not prevent denervation-induced
atrophy in slow-dominant muscle
Next we sought to examine whether MST1 kinase defi-
ciency also affects the progression of denervation-induced
atrophy in slow-dominant soleus muscles from adult mice.
Western blotting and densitometry revealed that, unlike in
fast-dominant muscles, protein levels of MST1 and MST2
kinases were not altered in atrophic soleus muscles
compared with contralateral levels (Additional file 3). Two
weeks after denervation, WT soleus muscle mass
decreased to 82.8% ± 0.05% and MST1 deficient soleus
muscle mass remained 76.4% ± 0.03% of their contralateral
levels (Figure 3G), indicating that MST1 deficiency did not
prevent the progression of denervation-induced atrophy in
slow-dominant soleus muscle.
The enriched expression of MST1 kinase in slow-domi-
nant soleus muscle encouraged us to investigate whether
MST1 kinase activity contributes to the determination of
muscle fiber type composition within the skeletal mus-
cles. In diaphragm muscle obtained from adult MST1
deficient mice, type I fiber content was not significantly
different from that of WT littermates (Additional file 4),
indicating that MST1 kinase deficiency did not affect dia-
phragmatic myofiber composition. Interestingly, we
observed a mildly increased content of type I fiber
(Figure 3H, I) in MST1 deficient soleus muscle. In soleus
muscles from adult wild type mice, type I fibers account
for about 44% of total muscle content; while in MST1
deficient soleus muscles, about 50% of fibers are MHC I
expressing type I fibers, suggesting that MST1 kinase
deletion leads to a moderate slow-ward fiber type transi-
tion of soleus muscle (Figure 3I).
MST1 deficiency reduces FOXO3a-dependent transcription
of Atrogin-1 and LC3 genes in muscle atrophy
The atrophy resistant phenotype of MST1 deficient fast
muscles encouraged us to investigate the expression of the
genes functionally involved in protein degradation and
autophagy during muscle atrophy, including the two major
E3 ligases identified in muscle wasting studies, Atrogin-1
and MuRF-1, as well as LC3 and Bnip3, which are involved
in an activated autophagy pathway [9,45]. Through quanti-
tative PCR, we observed significant increases in expression
of Atrogin-1 and MuRF-1 genes in both WT and MST1
deficient atrophic gastrocnemius muscles at post-denerva-
tion Day 3 (Figure 4A, D). Expression of autophagy related
Bnip3 and LC3 genes did not show apparent increases
upon contralateral levels (Figure 4B, C), indicating acti-
vation of the ubiquitin-proteasome system is prior to acti-
vation of the autophagy pathway in early stages of
neurogenic muscle atrophy. Thus, the degradation of myo-
fiber proteins immediately following onset of atrophy is
potentially through the ubiquitin-proteasome system.
Interestingly, increase in Atrogin-1 gene expression in
MST1 deficient gastrocnemius muscles was suppressed by
approximately 40% compared with WT atrophic muscles
(Figure 4A). Relative expressional levels of the MuRF-1
gene were higher in atrophic MST1 deficient muscles
than that of WT although statistically not significant
(Figure 4D). Seven days after denervation, the relative
expressional levels of Atrogin-1, MuRF-1, LC3 and Bnip3
genes were all increased upon contralateral level in both
WT and MST1 deficient atrophic muscles (Figure 4E-H).
However, increases in expression of Atrogin-1 and LC3
were statistically less dramatic in atrophic MST1 deficient
muscles compared with WT (Figure 4E, F), indicating
that these genes were much less activated in MST1 defi-
cient muscles compared with those of WT during muscle
atrophy.
During the process of autophagy, LC3 I is converted to
LC3 II through proteolysis and lipidation [46,47]. How-
ever, recent evidence showed that up-regulated autophagy
activity was also accompanied by an increased total pro-
tein level of LC3 II but not the conversion ratio of LC3
II/I [48]. In our study, LC3 blotting and densitometry
revealed up-regulation of total and activated LC3 proteins
were less dramatic in MST1 deficient atrophic muscles
than those of WT (Figure 4I-K). Although the ratio of
conversion of LC3 into the activated forms (LC3 II/I) did
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Figure 3 MST1 deficiency protects fast- but not slow-dominant skeletal muscles against denervation-induced atrophy. Sciatic denervation
was performed on three- to five-month-old adult WT and MST1 KO mice littermates. Three pairs of WT and MST1 KO mice were sacrificed at Day
7 after denervation and the other three pairs were examined at Dday 14. A. Mass of denervated gastrocnemius muscles from MST1 deficient mice
remained at 79.18% ± 1.73% (on Day 7) and 67.14% ± 2.37% (on Day 14) of the contralateral muscles, both of which were significantly higher than
64.83% ± 2.01% and 53.53% ± 1.09% in WT mice, respectively. B. Seven and 14 days after denervation, mass of denervated TA muscles from MST1
KO mice remained at 74.43% ± 1.36% and 66.35% ± 2.56% of contralateral levels, whereas WT TA muscle mass remained at 64.47% ± 2.4% and
50.81% ± 2.5%, respectively. C. Representative images of a-laminin staining on contralateral and denervated TA muscle cryosections, indicating
myofiber size was better preserved in MST1 deficient TA muscles at Day 14 after denervation. D. Fourteen days after denervation, averaged
myofiber cross-sectional area of denervated TA muscle decreased to 71.61% ± 5.11% of the contralateral level in MST1 KO mice and 55.56% ±
0.87% in WT mice. E and F. TA myofiber size distribution showed a suppressed leftward shift in MST1 deficient TA muscles (F) 14 days after
denervation, indicating less atrophy compared with WT muscles (E). G. Fourteen days after denervation, WT soleus muscle mass remained at
82.78% ± 5.32% of contralateral and MST1 deficient soleus muscle mass remained at 76.43% ± 2.45% of its contralateral level. H. Representative
images of MHC I staining on contralateral and post-denervated Day 14 soleus muscles from WT and MST1 KO mice. WT and MST1 deficient soleus
muscles developed similar level of atrophy 14 days after denervation. I. The ratio of slow-to-fast fiber content was significantly higher in MST1
deficient contralateral soleus muscles than that of WT muscles. 14 days after denervation, the ratios of slow-to-fast fiber content in WT and MST1
deficient soleus muscle were both increased. * P < 0.05 compared with wild type by two-tailed Student’s test.
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not show a difference between WT and MST1 KO groups
(Figure 4L), our data revealed that activation of LC3 gene
expression in atrophic muscles was at least partially sup-
pressed due to MST1 deficiency.
Among the genes examined in atrophic muscles,
Atrogin-1, Bnip3 and LC3 were shown to be regulated
by the FOXO3a transcription factor. FOXO3a is able
to bind to the promoter regions of the genes encoding
Atrogin-1, LC3, Bnip3 and Gabarap1, and induces dra-
matic increases in the expression of these atrogenes in
muscles to initiate atrophy [13-15]. Thus, our results
revealed that deficiency in MST1 kinase suppressed
the activation of FOXO3a regulated genes in atrophic
muscles, indicating that the activity of this transcrip-
tion factor was differentially modulated in WT and
MST1 deficient atrophic muscles.
Figure 4 Expression of atrophy related genes in denervated gastrocnemius muscles from WT and MST1 KO mice. A-D. Quantitative PCR
results showed three days after denervation, Atrogin-1 mRNA levels in WT and MST1 deficient gastrocnemius muscle were both increased (by
4.57 ± 0.70 folds and 2.68 ± 0.28 folds of the contralateral level, respectively). The increases in mRNA levels of LC-3 (1.76 ± 0.35 and 1.54 ± 0.15,
WT vs. MST1 KO) and Bnip-3 were both less than two-fold and there is no significant difference in the WT and MST1 deficient muscles. MuRF-1
mRNA levels were upregulated to 9.51 ± 0.88 and 24.07 ± 7.68 folds in WT and MST1 deficient muscles, respectively. E-H. At Day 7 after
denervation, the mRNA levels of muscle atrophy-related genes were significantly increased in both WT and MST1 deficient denervated muscles.
The mRNA levels of Atrogin-1 and LC3 in denervated WT muscles (4.45 ± 0.47 and 4.43 ± 0.26 folds increased, respectively) were both
significantly higher than that of MST1 KO mice (1.82 ± 0.12 folds and 2.91 ± 0.06 folds, respectively). Bnip-3 and MuRF-1 mRNA levels were also
increased in denervated WT and MST1 deficient muscles but showed no differences between the genotypes. I-L. The protein levels of total LC3
and lapidated form (LC3 II) were both increased in MST1 deficient and WT muscles. Total LC3 protein was increased at 3.95 ± 0.37 folds in WT
denervated muscle and 2.65 ± 0.48 folds in MST1 deficient denervated muscles. The LC3 II protein level in WT denervated muscle was increased
3.95 ± 0.31 folds and 2.44 ± 0.54 folds in MST1 deficient muscles, respectively. The ratio of LC3 II/LC3 I was 1.68 ± 0.20 and 1.31 ± 0.12 in WT
and MST1 deficient muscles after denervation. * P < 0.05 by two-tailed Student’s test.
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MST1 phosphorylates FOXO3a at Serine207 and promotes
its nuclear translocation at early stage of muscle atrophy
It has been shown that FOXO3a shuffles into myofiber
nucleus and its activity is up-regulated upon atrophy sti-
muli [13]. The subcellular location and activity of FOXO3a
are precisely determined by multiple post-translational
modification mechanisms [19]. The suppressed up-regula-
tion of FOXO3a-mediated atrogenes in MST1 deficient fast
muscles undergoing atrophy leads us to investigate whether
the activation of FOXO3a is differentially modulated in
atrophic WT and MST1 deficient muscles.
It has been previously reported that MST kinases are
functionally upstream of FOXO transcription factors in a
MST-FOXO signaling cascade. Through phosphorylating
FOXO factors at a conserved serine site, MST kinases
promote nuclear translocation of FOXO factors and acti-
vation of pro-apoptotic genes, thus promoting apoptosis
of neurons upon oxidative stress [30]. In order to elucidate
whether such a MST-FOXO signaling mechanism con-
tributes to modulating the subcellular localization and
activity of FOXO3a during the pathogenic process of neu-
rogenic muscle atrophy, we examined the phosphorylation
status of FOXO3a at Ser207 in both WT and MST1 defi-
cient TA muscles undergoing atrophy.
We first confirmed the absence of MST1 protein in fast-
and slow-dominant muscles from adult MST1 KO mice
(Figure 5A and Additional file 3A). Western blotting and
densitometry revealed three days after denervation, the
phosphorylation level of FOXO3a by MST kinase at
Ser207 was significantly up-regulated by 29.5% ± 0.07%
(Figure 5A, B) in WT TA muscle, indicating the activation
of FOXO3a transcription factor due to the up-regulation
of MST kinases. Interestingly, the phosphorylation of
FOXO3a at Ser207 was not increased in MST1 deficient
muscles during atrophy, indicating that immediately fol-
lowing denervation, the phosphorylation of FOXO3a at
Ser207 was mediated by MST1 but not MST2. Three and
seven days after denervation, the FOXO3a protein amount
was continuously increased in WT TA muscles and the
total protein level of FOXO3a was consistently higher in
MST1 deficient muscles (Figure 5C), suggesting a poten-
tial compensatory effect by FOXO3a gene expression
under a MST1 deficient background. Three and seven
days after denervation, the protein level of MST1 kinase
was up-regulated in WT muscle (Figure 5A, D); while
the protein level of MST2 kinase was also increased in
both WT and MST1 deficient muscles to similar levels,
indicating there was no functional compensation by MST2
kinase due to MST1 deficiency during muscle atrophy
(Figure 5A, E). Further study indicated that seven days
after denervation, the phosphorylation of FOXO3a by
MST1 kinase was decreased in atrophic muscles. Thus the
activation of FOXO3a was potentially tightly controlled by
a dephosphorylation mechanism to restrict activation of
this transcription factor.
It has been previously shown that phosphorylation of
FOXO by MST kinases was sufficient to promote its dis-
sociation from 14-3-3 proteins in cytosol and to promote
nuclear accumulation of FOXO transcription factors [30].
In order to clarify whether MST1-mediated phosphoryla-
tion of FOXO3a also contributes to modulating its subcel-
lular location during skeletal muscle atrophy, we examined
the subcellular distribution of FOXO3a in atrophic muscles
obtained from denervated adult MST1 deficient mice and
their WT littermates. We observed a dramatic increase in
nuclear localization of FOXO3a in both WT and MST1
deficient atrophic muscles (Figure 6A) at Day 3 after
denervation. However, the level of nuclear accumulated
FOXO3a in MST1 deficient muscles was significantly less
compared to that in WT muscles (Figure 6B). In order to
further elucidate whether the phosphorylation of FOXO3a
on Ser207 is directly involved in its nuclear transportation,
we examined the subcellular distribution of Ser207-phos-
phorylated FOXO3a on atrophic muscle sections. As
shown in Figure 6C, D, nuclear localized Ser207-phos-
phorylated FOXO3a was significantly increased in WT
atrophic muscles at Day 3 after denervation. In contrast,
nuclear accumulation of Ser207-phosphorylated FOXO3a
was dramatically suppressed in MST1 deficient muscles
(Figure 6C, D).
Taken together, our results revealed that the up-regu-
lated MST1 kinase was functionally involved in activation
of FOXO3a through phosphorylation at Ser207, and thus
promoted its nuclear translocation in fast-twitch myofibers
undergoing atrophy; MST1 deficiency result in less activa-
tion of FOXO3a and suppressed nuclear translocation of
this transcription factor, and thus lead to an atrophy-resis-
tant phenotype in fast-dominant muscles from adult
MST1 KO mice.
Discussion
In the present study we have identified the role of
MST1 kinase in mediating the pathologic process of
neurogenic muscle atrophy. Upon denervation, MST1
kinase was immediately up-regulated in fast-dominant
muscles. The up-regulated MST1 kinase directly phos-
phorylated FOXO3a transcription factor at Ser207, and
promoted its nuclear translocation and activation of
atrogenes (Figure 7).
MST1/2 was widely expressed in multiple striated
muscles, including cardiac muscle, and slow- and fast-
dominant skeletal muscles (Figure 1A). Interestingly, the
expression of MST1 kinase was enriched in skeletal mus-
cles at neonatal stages (Figure 1E, F), suggesting that MST1
kinase was potentially involved in regulating postnatal
development of myofibers. It has been generally identified
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that a group of gene regulatory mechanisms functioning
during early development of an organism are re-deployed
under certain pathogenic conditions in adulthood. Here we
identified that the MST1 gene expression was rapidly
increased during the process of neurogenic fast muscle
atrophy, thus MST1 represented one such re-deployed
developmental gene program in fast muscles undergoing
atrophy. Further studies using the MST1 deficient mouse
model identified that the role of the up-regulated MST1
kinase was to promote the development of muscle atrophy,
rather than functions as an adaptive mechanism to prevent
rapid loss of muscle mass. We had also observed an
enriched MST1 protein amount in slow-dominant soleus
muscle compared with fast-dominant muscles under phy-
siological conditions (Figure 1A, B). However, deficiency in
MST1 leads to only a moderate switch in fiber type compo-
sition in soleus muscle (Figure 3 H). Thus, aims of future
studies will be directed to investigate the role of MST1 in
muscle development at early postnatal stages as well as
whether MST1 contributes to maintaining the fiber type
Figure 5 MST1 phosphorylates FOXO3a at Ser207 during muscle atrophy. A. Representative western blotting of MST1/2 and FOXO3a in
atrophic TA muscles. B. Phosphorylation of FOXO3a at serine 207 by MST1 kinase was increased (by 29.5% ± 7.40%) in WT TA muscles but not
in MST1 deficient muscles at denervation Day 3. FOXO3a Ser207 phosphorylation was decreased both in WT and MST1 KO muscles at Day 7
after denervation. C. Total FOXO3a protein level was continuously increased at Day 3 and Day 7 after denervation in WT TA muscles. D and E.
Both the expression levels of MST1 and MST2 kinases were increased in atrophic muscles. MST2 protein levels were similarly increased in wild
type and MST1 deficient muscles and WT muscles after denervation. At Dday 7 after denervation, comparing with the contralateral, the protein
levels of MST2 kinase were increased 2.91 ± 0.15 and 2.92 ± 0.10 folds in the atrophic TA muscles obtained from WT and MST1 KO mice,
respectively. * P < 0.05 by two-tailed Student’s test.
Figure 6 MST1 promotes nuclear translocation of FOXO3a through phosphorylation at Ser207. A and C. Representative immunostaining
using pan-FOXO3a and Ser207-phosphorylated FOXO3a antibodies on TA muscle sections obtained on denervation Day 3. B. At Day 3 after
denervation, 41.46% ± 3.07% and 27.51% ± 2.28% of the total myofiber nucleus were stained with FOXO3a in WT and MST1 deficient TA
muscles, respectively. D. At Day 3 after denervation, 32.63% ± 1.82% and 12.10% ± 1.49% of total TA muscle nuclei stained with serine 207-
posphorylated FoxO3a in WT and MST1 mice, respectively. *** P < 0.0001 by two-tailed Student’s test..
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composition of skeletal muscle. In skeletal muscles, under
both physiological and pathogenic conditions, MST1 kinase
deficiency did not lead to expressional nor functional com-
pensations by MST2 kinase (Figure 5A, E), suggesting
MST1 and MST2 kinases play differential roles in main-
taining the pathophysiological homeostasis of skeletal
muscles.
It is well characterized that remodeling of gene expres-
sion in atrophic myofibers is orchestrated by multiple reg-
ulatory mechanisms [49]. FOXO3a transcription factor
has been shown to mediate up-regulation of genes
involved in both ubiquitin-proteasome and autophagy
pathways [14]. Studies have shown that inhibition of
FOXO3a in muscles treated with atrophic stimuli is cap-
able of preventing muscle from atrophying [17,50]. We
have previously shown that a conserved MST-FOXO sig-
naling mechanism mediates the apoptotic response of
neurons under oxidative stress [30]. In the present study,
we have identified that the MST-FOXO signaling mechan-
ism is also conserved in mouse skeletal muscles. MST1
phosphorylates and thus activates FOXO3a during neuro-
genic skeletal muscle atrophy, which provides a new mole-
cular mechanism to precisely determine the subcellular
location and activity of FOXO3a in myofibers undergoing
atrophy.
Immediately following denervation, phosphorylation
of FOXO3a at Ser207 was significantly enhanced (Fig-
ure 5A, B). Comparison between WT and MST1 deficient
skeletal muscles further revealed that the phosphoryla-
tion of FOXO3a at Ser207 was mainly mediated by MST1,
since a normalized level of Ser207-phosphorylated
FOXO3a was consistently lower in MST1 deficient mus-
cles under both normal and atrophic conditions. We had
also observed an increased FOXO3a protein level in
MST1 deficient fast muscles, which might reflect a func-
tional compensation by FOXO3a for MST1 deficiency.
Our results revealed that the subcellular location of
FOXO3a transcription factor in myofibers was controlled
by both Akt kinase and MST1 kinase in a counter-
balanced manner. Up-regulation of MST1 kinase function
following denervation further promoted nuclear accumu-
lation of FOXO3a and thus full development of muscle
atrophy. FOXO3a transcription factor is able to bind to
promoter regions of multiple atrophy related genes,
including Atrogin-1, LC3, Bnip3, Gabarapl1. Among these
atrogenes, we found that activation of FOXO3a by MST1
kinase especially affected the expression of Atrogin-1 and
LC3 genes, but not Bnip3. Our results suggested that a dif-
ferential post-translational modification status of FOXO3a
might potentially result in activation of different groups of
its target genes. However, the underlying mechanisms still
need to be elucidated in further studies.
The transcriptional mechanism mediating MST1 gene
expression is still not well understood, especially under
multiple pathophysiological conditions. During muscle
atrophy, many gene regulatory mechanisms have been
reported to be activated to promote expression of protein
degradation machineries, including myogenic factor myo-
genin and MyoD [16], NF-B [18], as well as FOXO tran-
scription factors [13]. The dramatic decrease in MST1
protein level in multiple striated muscles during postnatal
development indicates that MST1 is potentially regulated
by the muscle differentiation program. However, the mole-
cular mechanisms mediating the expression of MST1 dur-
ing both neonatal development and atrophic remodeling
need to be determined in further studies. We have observed
that both MST1 and MST2 kinase were up-regulated dur-
ing fast-dominant muscle atrophy. However, MST2 could
Figure 7 Schematic diagram of MST1’s function in mediating fast skeletal muscle atrophy. Within an innervated myofiber, Akt kinase is
active and MST1 kinase amount is restricted at low level. Thus FOXO3a is phosphorylated by Akt at multiple sites (Thr32, Ser253 and Ser315)
[53], and is restricted within the myofiber cytosol through interaction with 14-3-3 proteins. Denervation induces rapid up-regulation of MST1
kinase. MST1 phosphorylates FOXO3a at Ser207 and causes its translocation into myofiber nucleus to activate expression of LC3 and Atrogin-1
genes, which leads to rapid muscle mass loss during the progression of muscle atrophy.
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not compensate for MST1 deficiency in the aspects of
phosphorylating FOXO3a and promoting myofiber atro-
phy. Thus, the molecular mechanisms differentiating the
function of MST1 and MST2, as well as the function of
MST2 during muscle atrophy, need to be elucidated in
future studies.
The present study has focused on the biological con-
sequence of an up-regulated MST1 kinase in atrophic
muscles and its downstream molecular mechanisms. By
elucidating the MST1-FOXO3a signaling mechanism in
neurogenic muscle atrophy, we provide a potential ther-
apeutic target for the clinical treatment of muscle
atrophy.
Methods
Animal and muscle atrophy models
The use of animals and experimental procedures were
approved by the Institutional Animal Use and Care Com-
mittee of Institute of Biophysics at Chinese Academy of
Sciences. Generation of MST1 deficient mice was
described previously [44]. For denervation studies, three-
to five-month-old WT (n = 6) and MST1 KO (n = 7)
mice, both male and female, were used. For denervation-
induced muscle atrophy, mice were anesthetized, the scia-
tic nerve of left hind limb was exposed by blunt dissection
and a 3 mm piece was excised. An identical incision into
the right hind limb was made but the muscles remained
innervated to serve as control. Muscle samples were har-
vested at 3, 7, 10 and 14 days after the denervation sur-
gery. For disuse-induced muscle atrophy models, mice
tails were suspended and fixed onto a mobile hook
mounted to the cage. Hind feet of the mice were main-
tained 1 to 2 mm above the ground of the cage for 7 and
14 days. Mice were allowed free access to food and water
during the suspension period. For starvation experiments,
mice were deprived of food but allowed free access to
water for 48 hours. Muscle atrophy was evaluated by
decrease in muscle mass relative to individual contralateral
level.
Western blotting
Mice were anesthetized and muscles were quickly isolated,
and 10 to 20 mg pieces of the muscle tissues were homo-
genized in a SDS-PAGE sample buffer containing 2% SDS
and 1% b-mercaptoethanol, using a mechanical homogeni-
zer (Pro Scientific, Oxford, CT, USA). Protein samples
were heated at 85°C for five minutes and centrifuged to
remove the insoluble materials. Protein samples were then
resolved on either 10% or 15% SDS-PAGE with an acryla-
mide to bis-acrylamide ratio of 29:1. The resulting gels
were transferred to nitrocellulose membranes and probed
with primary antibodies as indicated. The signals of the
protein bands were visualized using enhanced chemilumi-
nescence method (GE Amersham, Pittsburgh, PA, USA).
Relative quantity of protein was analyzed by densitometry
using NIH Image J program (Bethesda, Maryland, USA).
Primary antibodies used in this study were as follows: anti-
MST1 (Cell Signaling Technology, Danvers, MA, USA),
anti-MST2 (Abcam, Cambridge, UK), anti-GAPDH
(Sigma, St. Louis, MO, USA), anti-LC3b (Cell Signaling
Technology, Danvers, MA, USA), anti-Ser207-phosphory-
lated FOXO3a (Invitrogen, Grand Island, NY, USA). A
monoclonal antibody against the C-terminal region of
mouse FOXO3a was prepared and used to detect
FOXO3a protein level from muscle lysates [51].
Quantitative PCR
Total RNA from the freshly isolated muscle tissues were
extracted using a Trizol method according to the manu-
facturer’s instruction (Invitrogen). Two micrograms of
RNA were converted to first strand cDNA using M-MLV
reverse transcriptase (Promega, Madison, WI, USA) fol-
lowing the manufacturer’s instruction. The quantitative
PCR were carried out with a Corbett 6200 machine
(Valencia, CA, USA) using a three-step protocol and PCR
reaction for each sample was performed in triplicate.
















For each primer pair, analysis of the melting curve was
performed to verify the specificity of the PCR product and
reaction conditions. Cycle numbers were measured using
Rotor-Gene 6000 software (Valencia, CA, USA) and
results were analyzed using the 2-ΔΔCt method.
Immunofluorescence
Muscles were freshly isolated and mounted in a plastic
bowl containing OCT (Thermo Scientific, Rockfield, IL,
USA), and the orientation of the muscle fibers was main-
tained to ensure the sectioning is performed in a trans-
verse manner. The mounted muscle tissues were frozen in
isopentane pre-chilled at -159°C for 30 to 40 seconds and
stored at -80°C. Transverse sectioning of the muscle tis-
sues was performed using a Leica CM3050S cryostat
(Wetzlar, Germany). Serial sections with 10 nm thickness
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were used for immunostaining and H&E staining follow-
ing a protocol as described previously [52]. Briefly, after
being rehydrated in PBS containing 0.05% Tween-20
(PBST) for 15 minutes and blocked in PBST containing
3% BSA for 30 minutes, muscle sections were probed with
primary antibodies at 4°C overnight. After three washes
with PBST for 10 minutes each, muscle sections were
incubated with fluorescent chromophore conjugated sec-
ondary antibodies. After three washes with PBST, muscle
sections were mounted and images were captured using a
Leica SP5 confocal microscopy. Muscle fiber areas
were quantified using NIH Image J software (Bethesda,
Maryland, USA). Primary antibodies used in immunos-
taining were as followings: anti-MHC I (Developmental
Hybridoma Bank, Iowa, USA) and anti-alpha-laminin
(Cambridge, UK).
Additional material
Additional file 1: MST1 protein level is increased in unloading-
induced muscle atrophy. A. Representative blots show MST1, but not
MST2, protein level was significantly increased in gastrocnemius muscles
seven days after hindlimb unloading. Neither MST1 nor MST2 protein
level was statistically altered in gastrocnemius muscles after 48-hour
starvation. B. Quantification of MST1 and MST2 protein levels in hindlimb
unloading- and starvation-induced muscle atrophy. *, P < 0.05 by two-
tailed Student’s test.
Additional file 2: Mass of fast-dominant TA and gastrocnemius
muscles are decreased in adult MST1 KO mice. Soleus, EDL, TA and
Gas muscles were isolated from three-to five month-old WT (n = 6) and
MST1 KO (n = 7) mice. Mass data of the muscles was normalized to
body weight data of the mice. *, P < 0.05 compared with wild type by
two-tailed Student’s test.
Additional file 3: MST1 kinase is not involved in denervation-
induced atrophy of slow dominant muscle. A and B. Western blotting
and densitometry showed neither MST1 nor MST2 kinase protein level
was altered in denervated soleus muscles.
Additional file 4: MST1 deficiency does not affect type I fiber
composition in diaphragm muscles. MHC I staining of muscle
cryosections showed similar type I fiber content in adult WT and MST1
KO diaphragm muscles.
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Gas: Gastrocnemius; KO: knockout; MST: Mammalian Sterile 20-like kinase;
PBS: phosphate-buffered saline; PBST: phosphate-buffered saline containing
0.05% Tween-20; PTM: post-translational modifications; Sol: soleus; TA: tibial
anterior
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